Table 1.
Target gene | PPE type | PPE features (PBSa length (nt), RTb template length (nt), and RT type) | Mutation type | Editing efficiencyi | Refs | |
---|---|---|---|---|---|---|
Desired | Undesired | |||||
BFP | PPE3b | 14, 12, M-MLVc | 2 bp Subsf | 4.40% | NRj | [2] |
BFP | PPE3b | 14, 12, CaMVd | 2 bp Subs | 3.70% | NR | [2] |
BFP | PPE3b | 14, 12, Retrone | 2 bp Subs | 2.40% | NR | [2] |
OsCDC48 | PPE2 | 12, 9, M-MLV | 6 bp Delg | 8.20% | 4.6% | [2] |
OsCDC48 | PPE3 | 12, 9, M-MLV | 6 bp Del | 21.80% | NR | [2] |
OsCDC48 | PPE3 | 12, 15, M-MLV | 3 bp Subs | 2.60% | NR | [2] |
OsCDC48 | PPE3b | 12, 9, M-MLV | 6 bp Del | 11% | NR | [2] |
OsCDC48 | PPE3b | 12, 9, CaMV | 6 bp Del | 5.80% | NR | [2] |
OsCDC48 | PPE3 | 10, 17, M-MLV | 1 bp Subs | 14.30% | NR | [2] |
OsCDC48 | PPE2 | 12, 13, M-MLV | 3 bp Insh | 1.98% | 0.7% | [2] |
OsCDC48 | PPE2 | 12, 18, M-MLV | 1 bp Subs | 5.70% | 3.8% | [2] |
OsCDC48 | PPE3b | 12, 13, M-MLV | 3 bp Ins | 1.88 | 0.03% | [2] |
OsCDC48 | PPE3b | 12, 18, M-MLV | 1 bp Subs | 3.0% | 2.0% | [2] |
OsCDC48 | PPE3b | 12, 18, CaMV | 1 bp Subs | 0.30 | NR | [2] |
OsCDC48 | PPE2 | 12, 15, M-MLV | 3 bp Del | ~0.05% | ~0.05% | [2] |
OsCDC48 | PPE3b | 12, 15, M-MLV | 3 bp Del | ~0.05% | ~0.05% | [2] |
OsALS | PPE2 | 10-12, 16-17, M-MLV | 1 bp Subs | 0.28% | 0.035% | [2] |
OsALS | PPE3 | 12-13, 13-16, M-MLV | 1 bp Subs | 0.35% | 0.52% | [2] |
OsDEP1 | PPE2 | 13, 13, M-MLV | 1 bp Subs | 0.10-0.3% | 0.03-0.3% | [2] |
OsDEP1 | PPE3 | 13, 11-13, M-MLV | 1 bp Subs | 0.10-0.3% | 0.1-0.2% | [2] |
OsEPSPS | PPE2 | 13, 11-20, M-MLV | 1 bp Subs | 0.80-1% | 0.3-0.6% | [2] |
OsEPSPS | PPE3 | 13, 20, M-MLV | 1 bp Subs | 2.27% | 2.66% | [2] |
OsEPSPS | PPE3 | 13, 17, M-MLV | 1 bp Subs | 1.55% | 1.53% | [2] |
OsEPSPS | PPE2 | 13, 17, M-MLV | 1 bp Subs | 0.10 | 0.2 | [2] |
OsEPSPS | PPE3 | 13, 17, M-MLV | 1 bp Subs | 0.10 | 0.2 | [2] |
OsLDMAR | PPE2 | 12, 15, M-MLV | 1 bp Subs | 0.35% | 0.1% | [2] |
OsLDMAR | PPE3 | 12, 15, M-MLV | 1 bp Subs | 0.73% | 0.1% | [2] |
OsGAPDH | PPE2 | 12, 16, M-MLV | 1 bp Subs | 1.40% | 0.16% | [2] |
OsGAPDH | PPE3 | 12, 16, M-MLV | 1 bp Subs | 1.60% | 0.24% | [2] |
OsAAT | PPE2 | 12, 13, M-MLV | 2 bp Subs | 0.12% | NR | [2] |
OsAAT | PPE2-R | 12, 13, M-MLV | 2 bp Subs | 0.04% | NR | [2] |
OsAAT | PPE3b | 12, 13, M-MLV | 2 bp Subs | 0.20% | NR | [2] |
OsAAT | PPE3b-R | 12, 13, M-MLV | 2 bp Subs | 0.45% | NR | [2] |
TaUbi10- | PPE2 | 13, 16, M-MLV | 1 bp Subs | 0.06% | 0.13% | [2] |
TaUbi10 | PPE3 | 13, 16, M-MLV | 1 bp Subs | 0.20% | 0.1% | [2] |
TaUbi10 | PPE2 | 12, 12, M-MLV | 1 bp Subs | 0.40-0.80% | 0.1-0.2% | [2] |
TaGW2 | PPE2 | 11, 11, M-MLV | 1 bp Subs | 0.30% | 0.03% | [2] |
TaGW2 | PPE3 | 11, 11, M-MLV | 1 bp Subs | 0.36% | 0.12% | [2] |
TaGASR7 | PPE2 | 12, 18, M-MLV | 1 bp Subs | 1.40% | 0.00% | [2] |
TaGASR7 | PPE3 | 12, 18, M-MLV | 1 bp Subs | 0.67% | 0.00% | [2] |
TaLOX2 | PPE2 | 12, 14, M-MLV | 1 bp Subs | 0.30% | 0.068% | [2] |
TaLOX2 | PPE3 | 12, 14, M-MLV | 1 bp Subs | 0.22% | 0.05% | [2] |
TaMLO | PPE2 | 12, 12, M-MLV | 1 bp Subs | 0.60% | 0.00% | [2] |
TaMLO | PPE3 | 12, 12, M-MLV | 1 bp Subs | 0.40% | 0.00% | [2] |
TaDME1 | PPE2 | 13, 14, M-MLV | 1 bp Subs | 1.30% | 0.07% | [2] |
TaDME1 | PPE3 | 13, 14, M-MLV | 1 bp Subs | 1.00% | 1.0% | [2] |
HPTII | PPE3-t | 13, 28, M-MLV | 3 bp Subs | 9.38% | NR | [26] |
OsALS | PPE2-WT | 13, 13, M-MLV | 1 bp Subs | 0.05% | NR | [27] |
OsALS | PPE2-V01 | 13, 13, M-MLV | 1 bp Subs | 0.10% | NR | [27] |
OsALS | PPE3b-V01 | 13, 13, M-MLV | 1 bp Subs | 0.10% | NR | [27] |
OsKO2 | PPE2-V01 | 13, 19, M-MLV | 1 bp Subs | 0.13% | NR | [27] |
OsDEP1 | PPE2-WT | 13, 13, M-MLV | 1 bp Subs | 0.01% | NR | [27] |
OsDEP1 | PPE2-V01 | 13, 13, M-MLV | 1 bp Subs | 0.15% | NR | [27] |
OsDEP1 | PPE3-V02 | 10, 22, M-MLV | 1 bp Subs | 0.03% | NR | [27] |
OsDEP1 | PPE3-V02 | 12, 19, M-MLV | 1 bp Subs | 0.23% | NR | [27] |
OsDEP1 | PPE3-V02 | 13, 13, M-MLV | 1 bp Subs | 0.67% | NR | [27] |
OsDEP1 | PPE3-V02 | 14, 17, M-MLV | 1 bp Subs | 0.35% | NR | [27] |
OsDEP1 | PPE3-V02 | 12, 11, M-MLV | 3 bp Ins | 0.90% | NR | [27] |
OsDEP1 | PPE3-V02 | 13, 17, M-MLV | 3 bp Ins | 0.50% | NR | [27] |
OsDEP1 | PPE3-V02 | 14, 25, M-MLV | 3 bp Ins | 0.075% | NR | [27] |
OsDEP1 | PPE3-V02 | 16, 14, M-MLV | 3 bp Ins | 1.53% | NR | [27] |
OsPDS | PPE2-V01 | 13, 13, M-MLV | 1 bp Subs | 0.06% | NR | [27] |
OsPDS | PPE3b-V02 | 10-16, 10-25, M-MLV | 3 bp Ins | 0.03-0.25% | NR | [27] |
OsPDS | PPE2-V01 | 10-16, 10-25, M-MLV | 3 bp Ins | 0.05-0.86% | NR | [27] |
OsPDS | PPE3-V02 | 10-16, 10-19, M-MLV | 3 bp Ins | 0.08-0.8% | NR | [27] |
OsEPSPS | PPE3b-V01 | 13, 23, M-MLV | 1 bp Subs | 0.36% | NR | [27] |
OsEPSPS | PPE3b-V01 | 13, 18, M-MLV | 1 bp Subs | 0.13% | NR | [27] |
OsGRF4 | PPE3b-V01 | 13, 15, M-MLV | 1 bp Subs | 0.16% | NR | [27] |
GFP, ALS, APO1 | Sp-PE2 | 13, 13, M-MLV | 1 bp Subs | 0-17.1% | NR | [28] |
OsSLR1 | Sp-PE3 | 13, 13, M-MLV | 3 bp Del | 0.00% | NR | [28] |
OsSPL14, APO2 | Sp-PE3 | 13, 13, M-MLV | 24 bp Ins | 0.00% | NR | [28] |
GFP, ALS, HPT | Sa-PE3 | 13, 16-34, M-MLV | 1 bp Subs | 0-32.65% | NR | [28] |
OsPDS | pPE2 | 13, 12, M-MLV | 1 bp Ins | 7.30% | NR | [29] |
OsPDS | pPE2 | 13, 13, M-MLV | 2 bp Ins | 12.5% | NR | [29] |
OsPDS | pPE2 | 13, 14, M-MLV | 3 bp Ins | 19.8% | NR | [29] |
OsPDS | pPE2 | 13, 11, M-MLV | 28 bp Del | 0.00% | NR | [29] |
OsPDS | pPE2 | 13, 11, M-MLV | 1 bp Subs | 0-31.25% | NR | [29] |
OsACC | pPE2 | 10-15, 10-34, M-MLV | 1 bp Subs | 0-14.6% | NR | [29] |
OsACC | pPE3 | 13, 10, M-MLV | 1 bp Subs | 10.4-18.75% | NR | [29] |
OsACC | pPE3b | 13, 10, M-MLV | 1 bp Subs | 6.25% | NR | [29] |
OsWX1 | pPE2 | 15, 31, M-MLV | 1 bp Subs | 7.30% | NR | [29] |
aPBS: primer binding site; bRT: reverse transcriptase; cM-MLV: Moloney murine leukemia virus; dCaMV: Cauliflower mosaic virus; eRetron: retron-derived RT (RT-retron) from E. coli BL21; fSubs: substitution; gDel: deletion; hIns: insertion; iData obtained from the published graph using the WebPlotDigitizer software (https://apps.automeris.io/wpd/); jNR: not reported.